Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA) - Full Text View

Purpose

Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity. Even though there have been many advances in the treatment of RA, psoriatic arthritis (PsA), and other inflammatory arthritis, doctors still do not know what causes this inflammation in joints. It is likely that RA occurs as a result of a complex combination of factors, including a person's genes; lifestyle choices, such as smoking and diet; and things in a person's environment, including bacteria or viruses. This study investigates the hypothesis that bacteria living in a person's mouth and/or intestinal tract are responsible, at least in part, for the development of Rheumatoid Arthritis. The investigators believe that by killing those bacteria with antibiotics, they might be able to understand how the immune system works and, maybe, what causes RA.

Condition	Intervention
Rheumatoid Arthritis Psoriatic Arthritis Periodontal Disease	Drug: doxycycline Drug: vancomycin


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor)
Official Title:	Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

Resource links provided by NLM:

Genetics Home Reference related topics: psoriatic arthritis rheumatoid arthritis

MedlinePlus related topics: Arthritis Rheumatoid Arthritis

Drug Information available for: Doxycycline Vancomycin Vancomycin hydrochloride Doxycycline monohydrate Doxycycline hyclate Doxycycline calcium

Genetic and Rare Diseases Information Center resources: Spondylarthropathy

U.S. FDA Resources

Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:

Alteration of Microbiota, Alteration of T Cell Function/Activation [ Time Frame: 6 months ]
Oral and intestinal microbiota, and T cell function and activation, will be assessed at baseline, and at 1, 2, 3, 4 and 5 months after baseline, to determine whether changes are associated with vancomycin treatment versus doxycycline treatment versus no treatment.

Results are reported as number of participants who experienced changes in oral/intestinal microbiota, T cell function/activation.

Methods/criteria to assess change in microbiota: change in relative abundance of microorganisms at genus and species level (as assessed high-throughput 16S rDNA sequencing).

Methods/criteria to assess change in T cell function/activation: change in percentage of inhibition of regulatory T cells as measured by interferon gamma levels in in-vitro assays.

Secondary Outcome Measures:

Mean Units Change in DAS28 From Baseline to 6 Months [ Time Frame: 6 months ]
DAS28 (disease activity score with 28 joint count). Possible score range: 0 to 10. This is a composite index calculated from 4 measures: two from a physician (28 tender joint count, 28 swollen joint count), one from the patient (patient global estimate of disease activity), and one laboratory biomarker (erythrocyte sedimentation rate or ESR). A score of 0 represents best possible health status (no apparent disease activity) and 10 represents worst possible.

The outcome is reported as mean change in DAS28 score from baseline to 6 months. The mean changes reported are negative values for downward change in score (i.e., improvement in health status).


Enrollment:	178
Study Start Date:	January 2010
Study Completion Date:	January 2013
Primary Completion Date:	January 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Rheumatoid Arthritis (RA) - doxycycline Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.	Drug: doxycycline doxycycline - 100 mg twice per day, for 2 months Other Name: Vibramycin
Active Comparator: Rheumatoid Arthritis (RA) - vancomycin Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks	Drug: vancomycin vancomycin, 250 mg four times a day, for 2 weeks Other Name: Vancocin
No Intervention: RA, PsA, healthy Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients. Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients. Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.

Detailed Description:

If you would like to participate in this study, we will first ask you several questions regarding the status of your arthritis, the medications you use or have used in the recent past, your social and dietary habits, and your medical and surgical history. If your answers tell us that you are the right patient for our study, we will go over a consent form which describes in more detail how we will study your intestinal and mouth bacteria, the immune cells in your blood and other genes, enzymes and proteins that tell us about your disease status.

If you have Psoriatic Arthritis (PsA) or are healthy with no history of arthritis, and would like to participate in this study, your participation would involve only one or two visits, and no treatment.

If you have Rheumatoid Arthritis (RA), your participation would involve six visits, and you would be randomly assigned to receive treatment with the antibiotic doxycycline, or the antibiotic vancomycin, or no antibiotic treatment.

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Rheumatoid Arthritis (RA) patients must meet American College of Rheumatology (ACR) criteria for RA
RA patients: duration of disease will be greater than 6 weeks and less than 2 years.
RA patients should have a Disease Activity Score 28 (DAS28) greater than or equal to 5.
PsA patients will be required to have disease duration and DAS28 similar to the RA patients, and to meet Moll and Wright criteria for PsA.
Allowable medications for both groups at study entry will include: prednisone (or equivalent) 5 mg or less per day (stable dose for at least 2 months); methotrexate 15 mg or less per week (stable dose for at least 2 months); and nonsteroidal anti-inflammatory drugs (NSAIDs) at FDA-approved doses.
Healthy controls will be age- and sex-matched individuals with no personal or family history of inflammatory arthritis.

Exclusion Criteria:

Patients who are unable to provide informed consent.
Pregnant or lactating women.
Recent (<3 months prior) use of any antibiotic therapy
Current consumption of probiotics
Current extreme diet (parenteral nutrition, macrobiotic diet, etc.)
Prednisone >5 mg/day or equivalent
Use of other disease-modifying antirheumatic drugs (DMARDs) with known antibiotic properties (Gold salts, hydroxychloroquine, sulfasalazine or minocycline).
Use of biologic DMARDs
Known inflammatory bowel disease
Known gastrointestinal (GI) tract neoplasm.
Recent GI tract infection (gastroenteritis, colitis, diverticulitis, appendicitis)
Chronic unexplained diarrhea.
Any GI tract surgery leaving permanent residua (e.g., gastrectomy; bariatric surgery; colectomy)
Significant liver, renal or peptic ulcer disease, defined as:
- Liver: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal (ULN)
- Renal: Creatinine >1.5 or endstage renal disease
- Peptic ulcer disease: recent ulcer or GI bleed (within past 12 months)
Inability or unwillingness to abstain from alcohol consumption.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01198509

Locations


United States, New York
NYU Hospital for Joint Diseases
New York, New York, United States, 10003
Bellevue Hospital
New York, New York, United States, 10016

Sponsors and Collaborators

New York University School of Medicine

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Memorial Sloan Kettering Cancer Center

Investigators


Principal Investigator:	Steven B. Abramson, MD	New York University School of Medicine
Study Director:	Jose U. Scher, MD	New York University School of Medicine

More Information

Publications:

Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, Lipuma L, Attur M, Pillinger MH, Weissmann G, Littman DR, Pamer EG, Bretz WA, Abramson SB. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012 Oct;64(10):3083-94. doi: 10.1002/art.34539.

Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, Su J, Yin F, Ding AH, Zanin-Zhorov A, Dustin ML, Tao J, Craft J, Yin Z, Feng JQ, Abramson SB, Yu XP, Liu CJ. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011 Apr 22;332(6028):478-84. doi: 10.1126/science.1199214. Epub 2011 Mar 10.

Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013 Nov 5;2:e01202. doi: 10.7554/eLife.01202.

Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol. 2011 Aug 23;7(10):569-78. doi: 10.1038/nrrheum.2011.121. Review.

Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol. 2012;30:759-95. doi: 10.1146/annurev-immunol-020711-074937. Epub 2012 Jan 6. Review.

Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. 2011 Oct 20;10(4):311-23. doi: 10.1016/j.chom.2011.10.004. Review.

Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol. 2014 Jan;26(1):101-7. doi: 10.1097/BOR.0000000000000008. Review.

Scher JU, Abramson SB. Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease? Arthritis Res Ther. 2013;15(5):122.


Responsible Party:	New York University School of Medicine
ClinicalTrials.gov Identifier:	NCT01198509 History of Changes
Other Study ID Numbers:	09-0658 RC2AR058986 ( U.S. NIH Grant/Contract )
Study First Received:	September 8, 2010
Results First Received:	September 3, 2014
Last Updated:	December 31, 2014

Keywords provided by New York University School of Medicine:


rheumatoid arthritis psoriatic arthritis periodontitis microbiota microbiome	vancomycin doxycycline T cell Th17

Additional relevant MeSH terms:


Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic Periodontal Diseases Gingival Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Spondylarthropathies Spondylarthritis Spondylitis	Spinal Diseases Bone Diseases Psoriasis Skin Diseases, Papulosquamous Skin Diseases Mouth Diseases Stomatognathic Diseases Vancomycin Doxycycline Anti-Bacterial Agents Anti-Infective Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents

ClinicalTrials.gov processed this record on July 27, 2017